Comprehensive studies on the pathology of hereditary breast cancer is needed to characterize variants of uncertain clinical significance (VUS) increasingly uncovered by WES [8,9], which may use lower thresholds for breast cancer mutation screening compared to targeted BRCA1/2 mutation screening. Here, BRCA1 is linked to breast carcinoma.